論文

査読有り
2007年10月

Clinical significance of high-Km 5 '-nucleotidase (cN-II) mRNA expression in high-risk myelodysplastic syndrome

LEUKEMIA RESEARCH
  • Keijiro Suzuki
  • ,
  • Takeshi Sugawara
  • ,
  • Tatsuo Oyake
  • ,
  • Toshiyuki Uchiyama
  • ,
  • Yusei Aoki
  • ,
  • Yasuhiko Tsukushi
  • ,
  • Shima Onodera
  • ,
  • Shigeki Ito
  • ,
  • Kazunori Murai
  • ,
  • Yoji Ishida

31
10
開始ページ
1343
終了ページ
1349
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.1016/j.leukres.2007.01.018
出版者・発行元
PERGAMON-ELSEVIER SCIENCE LTD

We analyzed cytosolic high-Km 5 '-nucleotidase (cN-II) and deoxycytidine kinase (dCK) mRNA expression in bone marrow mononuclear cells (BMMNC) of patients with high-risk myelodysplastic syndrome (MDS) using quantitative real-time polymerase chain reaction (rt-PCR). At diagnosis, the cN-II mRNA expression of patients was higher than that of healthy volunteers, but the dCK mRNA expression showed no significant difference. Patients with ara-C-containing chemotherapies whose BMMNC showed a high level of cN-II expression (greater than the median value) had shorter median overall survival (15 months versus 22 months, p < 0.01) and shorter median post-chemotherapy survival (10 months versus 16 months,p = 0.012). These data suggest that the expression level of cN-II mRNA might be a prognostic factor of high-risk MDS. (c) 2007 Elsevier Ltd. All rights reserved.

リンク情報
DOI
https://doi.org/10.1016/j.leukres.2007.01.018
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/17350683
Web of Science
https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=JSTA_CEL&SrcApp=J_Gate_JST&DestLinkType=FullRecord&KeyUT=WOS:000249545000004&DestApp=WOS_CPL
ID情報
  • DOI : 10.1016/j.leukres.2007.01.018
  • ISSN : 0145-2126
  • PubMed ID : 17350683
  • Web of Science ID : WOS:000249545000004

エクスポート
BibTeX RIS